Feasibility of Pharmaceutical Interventions in Elderly Heart Failure Patients.
RASP-HF
1 other identifier
interventional
29
1 country
1
Brief Summary
Heart failure therapies (e.g. beta blockers) have been successful in decreasing mortality rates, as well as diminishing hospitalizations. Also, pharmacist collaboration has been shown to have a beneficial impact on heart failure related outcomes. Regardless, a high residual event rate is to be noted. In our pilot study, we wished to document whether a clinical pharmacist could still play a role in the heart failure management of an elderly inpatient heart failure population.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable heart-failure
Started Apr 2013
Shorter than P25 for not_applicable heart-failure
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2013
CompletedFirst Submitted
Initial submission to the registry
May 26, 2014
CompletedFirst Posted
Study publicly available on registry
May 29, 2014
CompletedMay 29, 2014
May 1, 2014
4 months
May 26, 2014
May 26, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
the number of heart-failure related pharmaceutical interventions
during hospital stay (average of 14 days)
Secondary Outcomes (2)
acceptance rate of the pharmaceutical interventions
during hospital stay (average of 14 days)
clinical feasibility of the accepted interventions
during hospital stay (average of 14 days)
Study Arms (1)
clinical pharmacy intervention
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- years or older
- diagnosis of previous or new heart failure based on signs and symptoms as defined by the 'European Society of Cardiology guidelines on acute and chronic heart failure'
- diagnosis had to be confirmed by a recent echocardiogram
You may not qualify if:
- not Dutch speaking
- treatment restrictions had been applied on admission
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospitals Leuven
Leuven, Flemish Brabant, 3000, Belgium
Related Publications (1)
Walgraeve K, Van der Linden L, Flamaing J, Fagard K, Spriet I, Tournoy J. Feasibility of optimizing pharmacotherapy in heart failure patients admitted to an acute geriatric ward: role of the clinical pharmacist. Eur Geriatr Med. 2018 Feb;9(1):103-111. doi: 10.1007/s41999-017-0019-x. Epub 2018 Jan 4.
PMID: 34654283DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Karolien Walgraeve, PharmD
Universitaire Ziekenhuizen KU Leuven
- PRINCIPAL INVESTIGATOR
Lorenz R Van der Linden, PharmD
Universitaire Ziekenhuizen KU Leuven
- STUDY DIRECTOR
Jos Tournoy, MD, PhD
Universitaire Ziekenhuizen KU Leuven
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 26, 2014
First Posted
May 29, 2014
Study Start
April 1, 2013
Primary Completion
August 1, 2013
Study Completion
October 1, 2013
Last Updated
May 29, 2014
Record last verified: 2014-05